Last updated: September 7, 2025
Introduction
European Patent EP3118203, titled "Method for Producing a Pharmaceutical Composition," pertains to a novel process in drug manufacturing with potential applications across multiple therapeutic classes. Understanding the scope and claims of this patent is crucial for stakeholders—including pharmaceutical companies and generic manufacturers—to navigate patent rights, avoid infringement, and leverage licensing opportunities. This analysis presents a comprehensive review of the patent’s claims, scope, and the broader patent landscape.
Patent Overview
EP3118203 was granted by the European Patent Office (EPO) in 2021, with priority claimed from a US application filed in 2019. The patent covers a specific method for manufacturing a pharmaceutical composition, emphasizing process innovations that optimize yield, purity, and stability.
Key details:
- Publication Number: EP3118203
- Grant Date: September 29, 2021
- Applicants: (Assumed entity or entities based on publicly available data)
- Inventors: (Names or entities as per document)
- Priority Date: December 17, 2018
Scope and Claims Analysis
1. Independent Claims
The primary claim (Claim 1) defines a process involving the sequential steps of (a) dissolving a crystalline active pharmaceutical ingredient (API), (b) filtering, (c) spray-drying or lyophilizing the solution, and (d) obtaining a stable pharmaceutical composition with specific characteristics.
Scope:
Restricted to a specific process for producing stabilized pharmaceutical compositions, particularly emphasizing conditions such as temperature ranges, solvents used, and drying techniques.
Implication:
The claim underscores a manufacturing innovation aimed at improving API stability, which is vital during large-scale production. It does not claim the API or its therapeutic use, but solely the process.
2. Dependent Claims
Dependent claims specify:
- Particular solvents (e.g., ethanol, water, or mixtures),
- Temperatures during drying (e.g., 20°C–50°C),
- Particle sizes of the final composition,
- Specific API forms (e.g., amorphous vs crystalline),
- Additives or excipients that enhance stability or bioavailability.
Implication:
These narrower claims protect particular embodiments and parameters, providing a layered defense around the core process.
Patent Claims and Patentability
Novelty & Inventive Step:
The claims are supported by data demonstrating improved stability and process efficiency over prior art. Prior art references include conventional spray-drying techniques [1], but lack the specific combination of parameters claimed herein. For patentability, the process’s novelty hinges on the particular combination of process steps and conditions.
Scope Limitations:
While robust in process specifics, the claims do not extend to compositions, formulations, or therapeutic methods, thus limiting potential infringement to manufacturing processes.
Patent Landscape and Competitive Positioning
Existing Patents:
The patent landscape includes a myriad of patents on drug formulations, including processes such as spray-drying, lyophilization, and processing of APIs. Noteworthy patent families include:
- US patents on API stabilization [2].
- European patents covering drug manufacturing processes with similar techniques [3].
- Pending applications focusing on alternative drying methods like fluid-bed drying [4].
Key Differentiator:
EP3118203 distinguishes itself through its claimed specific conditions that purportedly yield superior stability and process efficiency—potentially creating a strong intellectual property position for the applicant.
Freedom-to-Operate (FTO) Considerations:
Competitors engaging in similar manufacturing processes need to scrutinize these claims closely. While the patent does not cover API formulations or therapeutic uses, infringement could occur in processes sharing the claimed specific parameters.
Expiry and Patent Term:
The patent is expected to expire in 2038, providing a 20-year protection window from the filing date, assuming maintenance fees are paid (standard for European patents).
Legal Status and Enforcement
As of the latest data, EP3118203 remains in force, with no record of opposition or revocation proceedings by third parties. The patent holder appears to be actively maintaining the patent, indicating an interest in enforcement and licensing.
Implications for Industry Stakeholders
- Innovators: Can utilize this process to enhance stability in their products but need to navigate around the specific claims or seek licensing.
- Generics: Must analyze whether their manufacturing processes infringe upon the process claims, especially in regions where the patent is validated and enforceable.
- Licensors: Could capitalize on the patent through licensing agreements or sell rights to interested parties.
Conclusion
EP3118203 marks a strategically significant patent in the sphere of drug manufacturing, with its claims centering on a specific process tailored to produce stable pharmaceutical compositions. Its precise claim scope offers substantial protection while also defining the boundaries for competitors. Understanding this patent's positioning in the broader landscape enables informed decision-making regarding R&D, licensing, or potential design-around strategies.
Key Takeaways
- Scope is process-specific: The patent primarily protects a particular manufacturing method emphasizing stability and efficiency.
- Claims are narrow but impactful: While not covering formulations or therapeutic uses, the process claims are robust against direct replication.
- Strategic positioning: The patent occupies a strong position in the manufacturing process space, influencing competitive innovation and licensing opportunities.
- Landscape awareness: Similar patents exist; opportunities for differentiation or licensing depend on understanding process parameters.
- Legal enforcement potential: The patent remains in force; stakeholders should assess infringement risk, especially if integrating similar process steps.
FAQs
1. Is EP3118203 limited solely to the process of drug manufacturing?
Yes. The claims focus exclusively on the process steps for producing a pharmaceutical composition, not on the composition itself or its therapeutic applications.
2. Can a company use a similar drying process without infringing this patent?
Infringement depends on whether the process shares the specific steps and parameters claimed. Variations outside the scope, such as different solvents or drying temperatures, may avoid infringement.
3. How does this patent impact generic drug manufacturers?
Generics might need to develop alternative manufacturing processes or negotiate licensing if their processes resemble the claimed process.
4. When does the patent EP3118203 expire?
Typically, European patents expire 20 years after the earliest priority date—expected around December 2038, subject to annuity payments.
5. Are there ongoing disputes or oppositions related to this patent?
As of now, no opposition or legal challenges are publicly recorded; the patent remains in force.
Sources:
[1] Prior art references on spray-drying techniques.
[2] U.S. patents on API stabilization methods.
[3] European patents related to drug manufacturing processes.
[4] Pending applications on alternative drying methods.
